U.S. Department of Health and Human Services

 Contact Info

Tel: 301-451-6990
Email: waldmanm@mail.nih.gov

 Select Experience

  • Staff ClinicianNIDDK, NIH2006-present
  • Clinical InstructorGlomerular Disease Institute2005-2006
  • Nephrology FellowHospital of the Univeristy of Pennsylvania2001-2005
  • ResidencyBaystate Medical Center1997-2001
  • M.D.Tufts University School of Medicine1997

 Related Links


Meryl A. Waldman, M.D.

Associate Research Physician, Kidney Disease SectionKidney Diseases Branch
  • Immune Mediated Glomerular Disease


A selection of recent and significant publications can be viewed below.

Waldman M, Sheiner E, Sergienko R, Shoham-Vardi I. Can we identify risk factors during pregnancy for thrombo-embolic events during the puerperium and later in life?. J Matern Fetal Neonatal Med. 2014 Jul 31; 28 (28; 9; 2014 Jul 31):1-15. [Full Text/Abstract]
Tseng J, Citrin DE, Waldman M, White DE, Rosenberg SA, Yang JC. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer. 2014 May 1; 120 (2014 May 1; 120; 9):1426-32. [Full Text/Abstract]
Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, Ito T, Ando H, Waldman MF, Thakurta A, Klippel A, Handa H, Daniel TO, Schafer PH, Chopra R. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 164 (164; 6):811-21. [Full Text/Abstract]
Gandhi AK, Mendy D, Waldman M, Chen G, Rychak E, Miller K, Gaidarova S, Ren Y, Wang M, Breider M, Carmel G, Mahmoudi A, Jackson P, Abbasian M, Cathers BE, Schafer PH, Daniel TO, Lopez-Girona A, Thakurta A, Chopra R. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol. 2014 Jan; 164 (164; 2; 2014 Jan):233-44. [Full Text/Abstract]
Waldman M, Austin HA 3rd. Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol. 2012 Oct; 23 (2012 Oct; 23; 10):1617-30. [Full Text/Abstract]
Waldman M, Austin HA 3rd. Controversies in the treatment of idiopathic membranous nephropathy. Nat Rev Nephrol. 2009 Aug; 5 (2009 Aug; 8; 5):469-79. [Full Text/Abstract]
Waldman M, Kopp JB. Parvovirus-B19-associated complications in renal transplant recipients. Nat Clin Pract Nephrol. 2007 Oct; 3 (2007 Oct; 10; 3):540-50. [Full Text/Abstract]
Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007 May; 2 (2007 May; 2; 3):445-53. [Full Text/Abstract]